Ambit will use its kinase platform to profile the specificity of certain compounds from GSK and Bristol-Myers. The platform consists of more than 170 quantitative, high-throughput kinase assays.
The company will also try to identify and characterize the protein targets of certain Pfizer compounds using its reverse screening technology that covers a large fraction of all human proteins.
Ambit has had previous collaborations with all three drug makers.